Occurrence of Secondary Malignancies in Chronic Myeloid Leukemia During Therapy with Imatinib Mesylate-Single Institution Experience

INTRODUCTION: Imatinib mesylate (IM) remains the treatment of choice for chronic myeloid leukemia (CML) showing a remarkable efficacy and offers a perspective for long disease-free survival. Due to prolonged administration of IM, the questions about the possible impact on the development of secondar...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mediterr J Hematol Infect Dis
Main Authors: Helbig, Grzegorz, Bober, Grażyna, Seweryn, Marek, Wichary, Ryszard, Tukiendorf, Andrzej, Sedlak, Lech, Oleksy, Tomasz, Kyrcz-Krzemień, Sławomira
Formato: Artigo
Idioma:Inglês
Publicado em: Università Cattolica del Sacro Cuore 2015
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4283924/
https://ncbi.nlm.nih.gov/pubmed/25574362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4084/MJHID.2015.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados